Latest Information Update: 03 Jul 2002
At a glance
- Originator SSP Co
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 03 Jul 2002 Discontinued - Phase-II for Asthma in Japan (unspecified route)
- 02 Dec 1999 SS Pharmaceuticals is now called SSP Co.
- 12 Dec 1996 Phase-II clinical trials for Asthma in Japan (Unknown route)